Colon cancer enzyme
Around every eighth cancer in Germany affects the large intestine (colon) or rectum.
In 2020, around 26,392 women and 32,120 men contracted it.
The diagnosis of colon cancer is thus made in one in 20 women and one in 17 men at some point in life.
About two thirds of diseases are discovered in the large intestine. The risk of colon cancer increases well into old age.
More than half of the patients become ill after the age of 70, only about 10 percent of the cancers occur before the age of 55. This corresponds to a comparatively high mean age of onset of 76 (women) and 72 years (men).
After a short-term increase, the age-standardized incidence rates began to decline around 2003, which has recently increased. Except for the ascending colon, the incidence rate decreases in all sections of the intestine.
The decline in age-standardized death rates over the past 10 years is even more pronounced for both sexes, at around 20 percent.
The relative 5-year survival rates with colon cancer for women and men are 63 percent and 62 percent, respectively.
Colon cancer enzyme No. 6 specifically helps to slow down the growth and spread of cancer cells in the organism. Cancer cells employ various strategies to avoid being destroyed by the body's immune defenses. For example, they camouflage themselves with a cover made of an endogenous material and can thus migrate to other parts of the body undetected. Our colorectal cancer enzyme No. 6 recognizes these camouflaged cells and destroys them. This way, metastases can be effectively prevented. Another deception of the cancer cells is also undermined by our colon cancer enzyme No. 6: The cancer cells produce structures that are classified as harmful and attacked by the immune system. Cancer cells that are still alive remain unmolested and have a free path to multiply. Colon cancer enzyme number 6 is able to split the deceptive structures.
Recommended daily dose: 2 x 1 capsule
